Daratumumab Receives FDA Approval for Transplant-Eligible Multiple Myeloma

On 26 September 2019, the US Food and Drug Administration (FDA) approved treatment for newly diagnosed adults eligible for autologous stem cell transplantation with multiple myeloma, in combination with bortezomib, thalidomide and dexamethasone: daratumumab (Darzalex) , a monoclonal antibody drug.
Darzalex was first approved in 2015, for multiple myeloma patients previously treated with proteasome inhibitors and immunomodulatory drugs, becoming the first approved monoclonal antibody drug for this disease. Many myeloma cells have abundant CD38 on their surfaces. CD38 has functions including signaling and tissue adhesion. Daratumumab binds CD38, inhibits its activity and causes tumor cell breakdown and destruction.
The CASSIOPEIA Study
An open-label, randomized, active-controlled phase 3 clinical trial , CASSIOPEIA compared newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation in two arms:
- Induction arm: daratumumab combined with bortezomib, thalidomide and dexamethasone (DVTd),
- Consolidation arm: bortezomib, thalidomide and dexamethasone (VTd).
Approval is based on CASSIOPEIA data, including progression-free survival (PFS), post-transplant day 100 stringent complete response (sCR), and post-transplant day 100 complete response (CR) rate.
Results
- PFS was better in the daratumumab arm than the VTd arm
- Median follow-up was 18.8 months, and median PFS had not been reached in either arm.
- DVTd reduced progression or death risk by 53% compared with VTd alone
- Post-transplant day 100 sCR was 28.9% in the DVTd arm and 20.3% in the VTd arm.
In newly diagnosed myeloma patients receiving daratumumab with bortezomib, thalidomide and dexamethasone, the most common (20%) side effects were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral neuropathy, peripheral edema, pyrexia and paresthesia. Effects occurring at least 5% more frequently in the DVTd arm were infusion reactions, nausea, neutropenia, thrombocytopenia, lymphopenia and cough. There was no significant difference in the number or types of serious side effects between arms.
The recommended daratumumab dose is 16 mg / kg.
Sources
fda.gov - 26 September 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.